167 CLINICAL CONSEQUENCES OF OFF-LABEL REDUCED DOSING OF NOACS IN AF S8: SUPPLEMENTAL REFERENCES. 1. Lafon T, Vallejo C, Hadj M, Laroche ML, Geniaux H. Misuse and adverse effects of new direct oral anticoagulants: a prospective observational study in patients admitted to an emergency unit of a French university hospital. Therapie. 2018;73(3):209–15. 2. Aguilar F, Lo KB, Quintero EE, Torres RJ, Hung WA, Albano JC, et al. Off-label direct oral anticoagulants dosing in atrial fibrillation and venous thromboembolism is associated with higher mortality. Expert Rev Cardiovasc Ther. 2021;19(12):1119–26. 3. Alcusky M, Hume AL, Fisher M, Tjia J, Goldberg RJ, McManus DD, et al. Dabigatran versus rivaroxaban for secondary stroke prevention in patients with atrial fibrillation rehabilitated in skilled nursing facilities. Drugs Aging. 2018;35(12):1089–98. 4. Alghadeer S, Hornsby L. Assessment of novel oral anticoagulant use within a community teaching hospital. Saudi Pharm J. 2017;25(1):93–8. 5. Alnsasra H, Haim M, Senderey AB, Reges O, Leventer-Roberts M, Arnson Y, et al. Net clinical benefit of anticoagulant treatments in elderly patients with nonvalvular atrial fibrillation: experience from the real world. Heart Rhythm. 2019;16(1):31–7. 6. Altay S, Yildirimtürk Ö, Çakman HA, Askin L, Sinan ÜY, Besli F, et al. New oral anticoagulants-TURKey (NOAC-TURK): multicenter cross-sectional study. Anatol J Cardiol. 2017;17(5):353–61. 7. Asahina C, Umetani K, Sano K, Yano T, Nakano S. Nine-year trend of oral anticoagulant use in patients with embolic stroke due to nonvalvular atrial fibrillation. J Arrhythm. 2020;36(5):883–9. 8. Chaudhry UA, Ezekowitz MD, Gracely EJ, George WT, Wolfe CM, Harper G, et al. Comparison of low-dose direct acting anticoagulant and warfarin in patients aged ≥80 years with atrial fibrillation. Am J Cardiol. 2021;152:69–77. 9. de Almeida JPHCL, Martinho AS, Girão A, Barreiro I, Milner J, Ferreira MJV, et al. Novel anticoagulants in an older and frail population with atrial fibrillation: the effect of inappropriate dosing on clinical outcomes. Eur Geriatr Med. 2020;11(5):813–20. 10. Eschler CM, Antelo A, Funk GC, Exadaktylos AK, Lindner G. High fluctuation between anticoagulants, frequent off-label dosing, and no difference concerning outcomes: results of a real-life cohort study. Am J Med. 2021;134(3):e165-70. 11. Frol S, Sernec LP, Hudnik LK, Šabovič M, Oblak JP. Effectiveness and safety of direct oral anticoagulants in the secondary stroke prevention of elderly patients: Ljubljana registry of secondary stroke prevention. Clin Drug Investig. 2020;40(11):1053–61. 12. George D, Devaraj NK, Rahmat SS, Mohamed S, Mohamad N. A national audit on the utilisation and documentation of dabigatran checklist for patients initiated on dabigatran. Med J Malaysia. 2019;74(5):425–30. 13. Gurevitz C, Giladi E, Barsheshet A, Klempfner R, Goldenberg I, Kornowski R, et al. Comparison of low and full dose apixaban versus warfarin in patients with atrial fibrillation and renal dysfunction (from a national registry). Am J Cardiol. 2021;159:87–93. 14. Haque H, Alrowily A, Jalal Z, Tailor B, Efue V, Sarwar A, et al. Direct oral anticoagulantrelated medication incidents and pharmacists’ interventions in hospital in-patients: evaluation using reason’s accident causation theory. Int J Clin Pharm. 2021;43(6):1693-704. 15. Inohara T, Holmes DN, Pieper K, Blanco RG, Allen LA, Fonarow GC, et al. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart. 2020;106(5):358–64. 16. Jackevicius CA, Lu L, Ghaznavi Z, Warner AL. Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2021;14(2):e007230. 8
RkJQdWJsaXNoZXIy MTk4NDMw